AssetMark Inc’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $365M | Sell |
616,050
-18,906
| -3% | -$9.42M | 0.74% | 28 |
|
|
2025
Q4 | $309M | Sell |
634,956
-10,952
| -2% | -$5.1M | 0.63% | 34 |
|
|
2025
Q3 | $271M | Sell |
645,908
-69,926
| -10% | -$23.5M | 0.58% | 36 |
|
|
2025
Q2 | $206M | Buy |
715,834
+197,384
| +38% | +$59M | 0.49% | 43 |
|
|
2025
Q1 | $160M | Buy |
518,450
+89,290
| +21% | +$30.6M | 0.44% | 45 |
|
|
2024
Q4 | $151M | Buy |
429,160
+9,203
| +2% | +$3.38M | 0.41% | 47 |
|
|
2024
Q3 | $150M | Buy |
419,957
+152,249
| +57% | +$51.4M | 0.43% | 48 |
|
|
2024
Q2 | $85.3M | Sell |
267,708
-2,454
| -0.9% | -$649K | 0.26% | 84 |
|
|
2024
Q1 | $62.1M | Sell |
270,162
-2,154
| -0.8% | -$486K | 0.2% | 105 |
|
|
2023
Q4 | $59.9M | Buy |
272,316
+2,088
| +0.8% | +$481K | 0.22% | 102 |
|
|
2023
Q3 | $61M | Sell |
270,228
-11,368
| -4% | -$2.62M | 0.24% | 87 |
|
|
2023
Q2 | $62.2M | Buy |
281,596
+11,173
| +4% | +$2.47M | 0.24% | 88 |
|
|
2023
Q1 | $60.6M | Buy |
270,423
+30,060
| +13% | +$7.41M | 0.25% | 87 |
|
|
2022
Q4 | $66.8M | Sell |
240,363
-25,992
| -10% | -$6.56M | 0.29% | 82 |
|
|
2022
Q3 | $55.8M | Buy |
266,355
+53,855
| +25% | +$12M | 0.26% | 86 |
|
|
2022
Q2 | $50.1M | Sell |
212,500
-44,831
| -17% | -$9.11M | 0.22% | 103 |
|
|
2022
Q1 | $46.2M | Sell |
257,331
-2,949
| -1% | -$562K | 0.19% | 117 |
|
|
2021
Q4 | $56.2M | Buy |
260,280
+16,785
| +7% | +$3.3M | 0.23% | 102 |
|
|
2021
Q3 | $44.9M | Buy |
243,495
+28,563
| +13% | +$5.63M | 0.2% | 122 |
|
|
2021
Q2 | $38.6M | Buy |
214,932
+24,510
| +13% | +$4.67M | 0.18% | 130 |
|
|
2021
Q1 | $31.9M | Buy |
190,422
+3,244
| +2% | +$541K | 0.16% | 141 |
|
|
2020
Q4 | $28.4M | Buy |
187,178
+17,217
| +10% | +$2.26M | 0.16% | 137 |
|
|
2020
Q3 | $17.2M | Buy |
169,961
+99,247
| +140% | +$10.9M | 0.11% | 160 |
|
|
2020
Q2 | $8.21M | Buy |
70,714
+70,617
| +72,801% | +$7.95M | 0.06% | 205 |
|
|
2020
Q1 | $9K | Buy |
97
+63
| +185% | +$5.99K | ﹤0.01% | 1012 |
|
|
2019
Q4 | $3K | Buy |
+34
| New | +$2.99K | ﹤0.01% | 1197 |
|
|
2019
Q3 | – | Sell |
-232
| Closed | -$18K | – | 1429 |
|
|
2019
Q2 | $18K | Buy |
232
+14
| +6% | +$1.31K | ﹤0.01% | 901 |
|
|
2019
Q1 | $26K | Hold |
218
| – | – | ﹤0.01% | 831 |
|
|
2018
Q4 | $24K | Sell |
218
-401
| -65% | -$46.5K | ﹤0.01% | 846 |
|
|
2018
Q3 | $79K | Buy |
619
+82
| +15% | +$10.1K | ﹤0.01% | 642 |
|
|
2018
Q2 | $61K | Buy |
537
+88
| +20% | +$9.67K | ﹤0.01% | 682 |
|
|
2018
Q1 | $50K | Buy |
449
+28
| +7% | +$3.56K | ﹤0.01% | 733 |
|
|
2017
Q4 | $62K | Sell |
421
-3
| -0.7% | -$381 | ﹤0.01% | 725 |
|
|
2017
Q3 | $50K | Sell |
424
-429
| -50% | -$54.8K | ﹤0.01% | 704 |
|
|
2017
Q2 | $110K | Buy |
853
+351
| +70% | +$43.8K | ﹤0.01% | 532 |
|
|
2017
Q1 | $67K | Buy |
502
+420
| +512% | +$63.6K | ﹤0.01% | 581 |
|
|
2016
Q4 | $12K | Sell |
82
-66
| -45% | -$8.43K | ﹤0.01% | 954 |
|
|
2016
Q3 | $18K | Sell |
148
-46
| -24% | -$5.53K | ﹤0.01% | 891 |
|
|
2016
Q2 | $20K | Buy |
+194
| New | +$21.6K | ﹤0.01% | 846 |
|
|
2016
Q1 | – | Sell |
-5
| Closed | -$1K | – | 1413 |
|
|
2015
Q4 | $1K | Buy |
+5
| New | +$728 | ﹤0.01% | 1281 |
|
Other funds holding UTHR
ACA
VPM
VCM
AssetMark Inc's UTHR Position: Q1 2026 in Review
AssetMark Inc reduced its United Therapeutics (UTHR) stake by 3% in Q1 2026, selling an estimated $9.42M and leaving 616,050 shares worth $365M. The position accounts for 0.74% of the portfolio, ranked #28.
AssetMark Inc first reported a position in UTHR in Q4 2015 and has held it in 40 quarters since. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- AssetMark Inc held 616,050 shares of United Therapeutics worth $365M as of Q1 2026.
- AssetMark Inc sold 18,906 United Therapeutics shares in Q1 2026, an estimated $9.42M.
- United Therapeutics made up 0.74% of AssetMark Inc's portfolio in Q1 2026, its #28 holding.
- AssetMark Inc first reported a position in United Therapeutics in Q4 2015 and has held it in 40 quarters since.
- 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.